Table of Contents
ISRN Ophthalmology
Volume 2011 (2011), Article ID 916789, 4 pages
http://dx.doi.org/10.5402/2011/916789
Research Article

Switching from Intravitreal Ranibizumab to Bevacizumab for Age-Related Macular Degeneration

Department of Ophthalmology, Faculty of Medicine, Oita University, Hasama-machi, Yufu-shi, Oita 879-5593, Japan

Received 11 October 2011; Accepted 15 November 2011

Academic Editors: B. Bui and U. U. Inan

Copyright © 2011 Kisaburo Yamada et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Klein, B. E. K. Klein, and K. L. P. Linton, “Prevalence of age-related maculopathy. The Beaver Dam Eye Study,” Ophthalmology, vol. 99, no. 6, pp. 933–943, 1992. View at Google Scholar · View at Scopus
  2. J. S. Heier, A. N. Antoszyk, P. R. Pavan et al., “Ranibizumab for treatment of neovascular age-related macular degeneration. A phase I/II multicenter, controlled, multidose study,” Ophthalmology, vol. 113, no. 4, pp. 633–642, 2006. View at Publisher · View at Google Scholar · View at PubMed
  3. P. K. Kaiser, B. A. Blodi, H. Shapiro, and N. R. Acharya, “Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration,” Ophthalmology, vol. 114, no. 10, pp. 1868–1875, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. P. K. Kaiser, D. M. Brown, K. Zhang et al., “Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results,” American Journal of Ophthalmology, vol. 144, no. 6, pp. 850–857, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. C. D. Regillo, D. M. Brown, P. Abraham et al., “Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1,” American Journal of Ophthalmology, vol. 145, no. 2, pp. 239–248, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. F. Kabbinavar, H. I. Hurwitz, L. Fehrenbacher et al., “Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 21, no. 1, pp. 60–65, 2003. View at Google Scholar · View at Scopus
  7. P. J. Rosenfeld, A. A. Moshfeghi, and C. A. Puliafito, “Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin®) for neovascular age-related macular degeneration,” Ophthalmic Surgery Lasers and Imaging, vol. 36, no. 4, pp. 331–335, 2005. View at Google Scholar · View at Scopus
  8. R. M. Rich, P. J. Rosenfeld, C. A. Puliafito et al., “Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration,” Retina, vol. 26, no. 5, pp. 495–511, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. R. L. Avery, D. J. Pieramici, M. D. Rabena, A. A. Castellarin, M. A. Nasir, and M. J. Giust, “Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration,” Ophthalmology, vol. 113, no. 3, pp. 363–372, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. I. A. Falkenstein, L. Cheng, V. L. Morrison, I. Kozak, A. M. Tammewar, and W. R. Freeman, “Standardized visual acuity results associated with primary versus secondary bevacizumab (Avastin) treatment for choroidal neovascularization in age-related macular degeneration,” Retina, vol. 27, no. 6, pp. 701–706, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. Z. F. Bashshur, A. Schakal, R. N. Hamam, C. P. El Haibi, R. F. Jaafar, and B. N. Noureddin, “Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration,” Archives of Ophthalmology, vol. 125, no. 10, pp. 1357–1361, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. M. Modarres, M. Naseripour, K. G. Falavarjani, A. Nikeghbali, M. Hashemi, and M. M. Parvaresh, “Intravitreal injection of 2.5 mg versus 1.25 mg bevacizumab (avastin) for treatment of CNV associated with AMD,” Retina, vol. 29, no. 3, pp. 319–324, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. R. Steinbrook, “The price of sight—ranibizumab, bevacizumab, and the treatment of macular degeneration,” New England Journal of Medicine, vol. 355, no. 14, pp. 1409–1412, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. J. Raftery, A. Clegg, J. Jones, C. T. Seng, and A. Lotery, “Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness,” British Journal of Ophthalmology, vol. 91, no. 9, pp. 1244–1246, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. M. L. Subramanian, S. Ness, G. Abedi et al., “Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial,” American Journal of Ophthalmology, vol. 148, no. 6, pp. 875–882, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. G. Landa, W. Amde, V. Doshi et al., “Comparative study of intravitreal bevacizumab (avastin) versus ranibizumab (lucentis) in the treatment of neovascular age-related macular degeneration,” Ophthalmologica, vol. 223, no. 6, pp. 370–375, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. M. A. Gamulescu, V. Radeck, B. Lustinger, B. Bianca Fink, and H. Helbig, “Bevacizumab versus ranibizumab in the treatment of exudative age-related macular degeneration,” International Ophthalmology, vol. 30, no. 3, pp. 261–266, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. D. S. Fong, P. Custis, J. Howes, and J. W. Hsu, “Intravitreal bevacizumab and ranibizumab for age-related macular degeneration: a multicenter, retrospective study,” Ophthalmology, vol. 117, no. 2, pp. 298–302, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. D. F. Martin, M. G. Maguire, G.-S. Ying, J. E. Grunwald, S. L. Fine, and G. J. Jaffe, “Ranibizumab and bevacizumab for neovascular age-related macular degeneration,” New England Journal of Medicine, vol. 364, no. 20, pp. 1897–1908, 2011. View at Publisher · View at Google Scholar · View at PubMed
  20. K. E. Stepien, P. J. Rosenfeld, C. A. Puliafito et al., “Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration,” Retina, vol. 29, no. 8, pp. 1067–1073, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. D. A. Karagiannis, I. D. Ladas, E. Parikakis et al., “Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?” Clinical Interventions in Aging, vol. 4, pp. 457–461, 2009. View at Google Scholar · View at Scopus
  22. S. J. Bakri, M. R. Snyder, J. M. Reid, J. S. Pulido, M. K. Ezzat, and R. J. Singh, “Pharmacokinetics of intravitreal ranibizumab (Lucentis),” Ophthalmology, vol. 114, no. 12, pp. 2179–2182, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. J. Gaudreault, D. Fei, J. C. Beyer et al., “Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits,” Retina, vol. 27, no. 9, pp. 1260–1266, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus